

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/  
Form 8-K  
July 28, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

July 28, 2005  
Date of Report (Date of earliest event reported)

-----  
ANTIGENICS INC  
(Exact name of registrant as specified in its charter)

-----  
DELAWARE                                       000-29089                                       06-1562417  
(State or other jurisdiction                    (Commission                                       (IRS Employer  
of incorporation)                              File Number)                                       Identification No.)  
  
630 Fifth Avenue, Suite 2100  
New York, NY 10111    10111  
(Address of principal executive offices)   (Zip Code)  
  
212-994-8200  
(Registrant's telephone number, including area code)  
-----

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02

Results of Operations and Financial Condition

On July 28, 2005, Antigenics Inc. announced its financial results for the quarter ended June 30, 2005. The full text of

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated July 28, 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: July 28, 2005

By: /s/ Garo H. Armen

-----

Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer

EXHIBIT INDEX

| Exhibit No. | Description of Exhibit            |
|-------------|-----------------------------------|
| -----       | -----                             |
| 99.1        | Press Release dated July 28, 2005 |